LPL Financial LLC Cuts Stock Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS)

LPL Financial LLC decreased its position in shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 35.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 29,451 shares of the company’s stock after selling 15,955 shares during the period. LPL Financial LLC’s holdings in Atossa Therapeutics were worth $28,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. Gallagher Capital Advisors LLC purchased a new stake in Atossa Therapeutics in the fourth quarter valued at about $25,000. Intech Investment Management LLC lifted its stake in shares of Atossa Therapeutics by 224.0% in the 4th quarter. Intech Investment Management LLC now owns 62,844 shares of the company’s stock valued at $59,000 after purchasing an additional 43,449 shares during the period. SG Americas Securities LLC grew its position in shares of Atossa Therapeutics by 148.2% during the 4th quarter. SG Americas Securities LLC now owns 103,865 shares of the company’s stock valued at $98,000 after acquiring an additional 62,016 shares during the period. Virtu Financial LLC increased its position in shares of Atossa Therapeutics by 311.1% in the fourth quarter. Virtu Financial LLC now owns 208,196 shares of the company’s stock valued at $197,000 after buying an additional 157,549 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in Atossa Therapeutics by 177.1% during the third quarter. JPMorgan Chase & Co. now owns 149,642 shares of the company’s stock valued at $227,000 after purchasing an additional 95,643 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

ATOS has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Atossa Therapeutics in a research note on Wednesday, March 26th. Ascendiant Capital Markets boosted their price target on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the company a “buy” rating in a research note on Monday, April 21st.

Atossa Therapeutics Stock Down 6.1 %

NASDAQ:ATOS opened at $0.84 on Friday. The company has a market capitalization of $108.89 million, a PE ratio of -3.83 and a beta of 1.46. The stock’s 50 day moving average price is $0.70 and its 200 day moving average price is $0.97. Atossa Therapeutics, Inc. has a 52-week low of $0.55 and a 52-week high of $1.81.

Atossa Therapeutics (NASDAQ:ATOS) last released its earnings results on Tuesday, March 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. As a group, sell-side analysts anticipate that Atossa Therapeutics, Inc. will post -0.22 EPS for the current fiscal year.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.